Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an ambispective, multicenter, observational real-world registry of patients with synchronous de novo oligometastatic prostate cancer, defined as prostate cancer with up to 10 extraregional metastatic lesions diagnosed at initial presentation or within 6 months of the primary diagnosis. The study will evaluate outcomes after comprehensive local and metastasis-directed treatment. Eligible patients receive definitive prostate-directed radiotherapy, which may include external-beam radiotherapy, external-beam radiotherapy with brachytherapy boost, or definitive prostate brachytherapy monotherapy in selected patients, together with stereotactic body radiotherapy to all identified extraregional metastatic lesions. Systemic therapy is given according to routine clinical practice and local multidisciplinary decisions. The registry is non-interventional. Participants are not assigned to treatment by the study protocol, and no experimental treatment, randomization, or protocol-mandated imaging schedule is used. The study collects de-identified data from routine medical records, including baseline disease characteristics, imaging, radiotherapy details, systemic therapy, radiographic progression, patterns of failure, subsequent treatments, adverse events, and survival. The study includes historical retrospective data, prospective follow-up of previously treated eligible patients, and prospective enrollment of newly eligible patients from the registry activation date. The main goal is to describe where and when prostate cancer progresses after comprehensive treatment of the prostate and all visible metastatic lesions, and to identify clinical and treatment-related factors associated with disease control and adverse events.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak gruczołu krokowego.
- •Pacjent jest mężczyzną.
- •Pacjent ma ukończone 18 lat.
- •Rak prostaty z rozsiewem (do 10 ognisk przerzutów) wykryty przy pierwszej diagnozie lub w ciągu 6 miesięcy od niej.
- •Pacjent otrzymuje pełne leczenie radioterapią gruczołu krokowego.
- •Pacjent otrzymuje leczenie radioterapią wszystkich wykrytych ognisk przerzutowych.
- •Dostępne są dane dotyczące leczenia i przebiegu choroby.
✗ Disqualifies
- •Więcej niż 10 ognisk przerzutów w momencie diagnozy.
- •Niekompletne leczenie ognisk przerzutowych.
- •Radioterapia gruczołu krokowego zastosowana tylko w celach łagodzenia objawów, a nie leczenia podstawowego.
- •Rak prostaty leczony wcześniej przed wykryciem rozsiewu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Affidea Nu-med Center of Oncological Diagnostics and Therapy
Zamość, Poland
Trial contact
Mateusz Bilski, MD, PhD
Paulina Kleban
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.